NEW YORK, NY (August 21, 2008) The leading figures in stem cell science will present the latest and most exciting breakthroughs in this revolutionary field of research at The New York Stem Cell Foundation's (NYSCF) third annual Translational Stem Cell Research Conference, October 14-15 at The Rockefeller University in Manhattan. The conference will focus on the dramatic advancements researchers are making in developing a better understanding of the major diseases of our time -- including diabetes, heart disease and cancer -- and how that knowledge will help them develop more effective treatments and, ultimately, cures.
Co-chaired by Douglas A. Melton, PhD, co-director of the Harvard Stem Cell Institute (HSCI), and Paul Nurse, PhD, president of The Rockefeller University, this year's NYSCF Translational Stem Cell Research Conference will feature two days of panels and presentations geared to both scientific and lay audiences. Drs. Melton and Nurse are both founding members of NYSCF's Medical Advisory Board.
"We are excited to provide this forum for the very best minds in the world of regenerative medicine to report their latest findings and exchange ideas," said Susan L. Solomon, NYSCF CEO. "It is equally important to provide a lay audience with a clear understanding of what we are learning from stem cell science, and how it is bringing us ever closer to clinical applications. Their support remains critical in advancing this pathfinding science."
The conference begins on Tuesday, October 14 with a day of panels designed to be of interest to a broad audience. The first panel, "Road to the Clinic: From Lab to Therapy," will be chaired and moderated by Harvard University Stem Cell Institute Director of Translational Medicine and NYSCF Scientific Advisor Lee Rubin, PhD, and will explore the process of taking research "from the lab bench to the bedside." Kevin Eggan, PhD, HSCI Principal Investigator and NYSCF Chief Scientific Of
|Contact: Adam Pockriss|
New York Stem Cell Foundation